Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib

被引：0

作者：

Yu, Helena Alexandra

Kerr, Keith

Rolfo, Christian Diego

Fang, Jian

Finocchiaro, Giovanna

Wong, Kam-Hung

Veillon, Remi

Kato, Terufumi

Yang, James Chih-Hsin

Nadal, Ernest

Raskin, Jo

Le, Xiuning

Karachaliou, Niki

Ellers-Lenz, Barbara

OBrate, Aurora

Stroh, Christopher

Piske, Nadine

Boesler, Carsten

Yang, Jinji

Mazieres, Julien

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Univ Aberdeen, Sch Med, Dept Pathol, Aberdeen, Scotland

[3] Aberdeen Royal Infirm, Aberdeen, Scotland

[4] Mt Sinai Med Syst, Tisch Canc Inst, Ctr Thorac Oncol, New York, NY USA

[5] Icahn Sch Med, New York, NY USA

[6] Peking Univ Canc Hosp, Dept Thorac Oncol, Beijing, Peoples R China

[7] IRCCS Humanitas Res Hosp, Milan, Italy

[8] Queen Elizabeth Hosp, Dept Clin Oncol, Hong Kong, Peoples R China

[9] CHU Bordeaux, Serv Malad Resp, Bordeaux, France

[10] Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan

[11] Natl Taiwan Univ, Ctr Canc, Dept Med Oncol, Taipei, Taiwan

[12] Catalan Inst Oncol, Dept Med Oncol, Barcelona, Spain

[13] Antwerp Univ Hosp UZA, Dept Pulmonol & Thorac Oncol, Edegem, Belgium

[14] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA

[15] Merck KGaA, Healthcare Business, Global Clin Dev, Darmstadt, Germany

[16] Merck KGaA, Healthcare Business, Dept Biostat, Darmstadt, Germany

[17] Merck KGaA, Healthcare Business, Global Med Affairs, Darmstadt, Germany

[18] Merck KGaA, Healthcare Business, Compan Diagnost & Biomarker Strategy, Darmstadt, Germany

[19] Merck KGaA, Healthcare Business, Clin Biomarkers & Technol, Darmstadt, Germany

[20] Guangdong Gen Hosp & Guangdong Acad Med Sci, Guangdong Lung Canc Inst, Dept Oncol, Guangzhou, Peoples R China

[21] Univ Paul Sabatier, CHU Toulouse, Toulouse, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9074

引用

下载

页数：1

共 50 条

[31] First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Ji, W.
Jiang, D.
Zhang, J.
Zhang, H.
Wang, Q.
Cang, S.
Li, X.
Tan, J.
Xiang, Y.
Li, X.
Liu, A.
Lu, S.
ANNALS OF ONCOLOGY, 2023, 34 : S1693 - S1693
[32] FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC
Planchard, D.
Janne, P. A.
Cheng, Y.
Lee, C. K.
Laktionov, K.
Yang, T. Y.
Yu, Y.
Kato, T.
Jiang, L.
Chewaskulyong, B.
Geater, S. Lucien
Maurel, J. M.
Rojas, C.
Havel, L.
Shepherd, F. A.
Tanaka, K.
Ghiorghiu, D.
Monterroso, E. Armenteros
Huang, X.
Yang, J. C. H.
ANNALS OF ONCOLOGY, 2023, 34 : S1311 - S1312
[33] FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC
Planchard, D.
Janne, P. A.
Cheng, Y.
Lee, C. K.
Laktionov, K.
Yang, T-Y.
Yu, Y.
Kato, T.
Jiang, L.
Chewaskulyong, B.
Geater, S. Lucien
Maurel, J-M.
Rojas, C.
Havel, L.
Shepherd, F. A.
Tanaka, K.
Ghiorghiu, D.
Monterroso, E. Armenteros
Huang, X.
Yang, J. C-H.
ANNALS OF ONCOLOGY, 2023, 34 : S1668 - S1668
[34] Durvalumab plus chemotherapy in patients (pts) with advanced EGFR mutation-positive (EGFRm) NSCLC whose disease progressed on first-line (1L) osimertinib: An ORCHARD study interim analysis
Cho, B. C.
Ahn, M. J.
Baik, C.
Garcia, R.
Goldman, J. W.
Kim, S-W.
Lee, J. S.
Nishio, M.
Ponce, S.
Salgia, R.
Teraoka, S.
Yoshida, T.
Yu, H. A.
Ambrose, H.
Cosaert, J.
Hartmaier, R.
Maidment, J.
Pluta, M.
Okamoto, I.
ANNALS OF ONCOLOGY, 2022, 33 : S34 - S35
[35] PD-L1 Expression, EGFR and KRAS Mutations in First-Line Therapy (1L) for Non-Small Cell Lung Cancer (NSCLC) Patients
Cronin-Fenton, D.
Dalvi, T.
Hedgeman, E.
Norgaard, M.
Petersen, L.
Hansen, H.
Fryzek, J.
Lawrence, D.
Walker, J.
Mellemgaard, A.
Rasmussen, T.
Shire, N.
Rigas, J.
Potter, D.
Hamilton-Dutoit, S.
Sorensen, H.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2084 - S2085
[36] Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers
Qi, Chuang
Cui, Huanxi
Chen, Dongsheng
JAMA ONCOLOGY, 2020, 6 (12)
[37] Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC
Minari, Roberta
Bordi, Paola
La Monica, Silvia
Squadrilli, Anna
Leonetti, Alessandro
Bottarelli, Lorena
Azzoni, Cinzia
Lagrasta, Costanza Anna Maria
Gnetti, Letizia
Campanini, Nicoletta
Petronini, Pier Giorgio
Alfieri, Roberta
Tiseo, Marcello
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (06) : E89 - E91
[38] Aumonertinib in EGFR-Mutant NSCLC Patients with Liver Dysfunction after TKI Treatment and NSCLC with Basic Hepatopathy as First-Line Therapy
Luo, F.
Liu, Y. Y.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S671 - S672
[39] ORCHARD platform study: Osimertinib plus datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib
De Langen, J.
Cho, B. C.
Piotrowska, Z.
Le, X.
Goldberg, S. B.
Goldman, J. W.
Okamoto, I.
Hewson, N.
Maidment, J.
Tang, K. H.
Veney, N.
Cosaert, J.
Lau, J.
Dressman, M.
Ambrose, H.
Riess, J. W.
Yu, H. A.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1091 - S1092
[40] Phase II study of erlotinib plus onartuzumab as first-line treatment for patients with MET-positive and EGFR-mutant NSCLC
Sakai, Hiroshi
Kishi, Kazuma
Seto, Takashi
Kozuki, Toshiyuki
Nishio, Makoto
Imamura, Fumio
Nokihara, Hiroshi
Satouchi, Miyako
Tahata, Takashi
Nakagawa, Kazuhiko
ANNALS OF ONCOLOGY, 2015, 26 : 82 - 82

← 1 2 3 4 5 →